Cite
HARVARD Citation
Erpenbeck, V. et al. (n.d.). Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers. Clinical pharmacology in drug development. 5 (4), pp. 306-313. [Online].